Antagonism between harmaline and longacting monoamine oxidase inhibitors concerning the effect on 5-hydroxytryptamine and norepinephrine metabolism in the brain.
D000470:Alkaloids / Q000494:pharmacology*; D001921:Brain / Q000378:metabolism*; D006246:Harmaline; D006791:Hostility; D008996:Monoamine Oxidase Inhibitors; D009448:Neurochemistry; D009638:Norepinephrine / Q000378:metabolism*; D010088:Oxidoreductases; D012701:Serotonin / Q000378:metabolism*
D000470:Alkaloids; D008996:Monoamine Oxidase Inhibitors; D012701:Serotonin; D006246:Harmaline; D010088:Oxidoreductases; D009638:Norepinephrine
ALKALOIDS/effects; ARTERENOL/metabolism; BRAIN/metabolism; OXIDASES; SEROTONIN/metabolism
Experientia. 1956 Dec 15;12(12):479-80
13397537
J Pharmacol Exp Ther. 1956 May;117(1):82-8
13320304
Proc Soc Exp Biol Med. 1957 Mar;94(3):433-5
13408282
Ann N Y Acad Sci. 1957 Mar 14;66(3):602-8
13425243
J Pharmacol Exp Ther. 1957 Apr;119(4):453-60
13429452
Proc Soc Exp Biol Med. 1958 Apr;97(4):748-51
13554470
Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1958;232(3):499-506
13552728
Schweiz Med Wochenschr. 1957 Dec 14;87(50):1532-4
13519103
Science. 1958 Mar 28;127(3300):704
13529039
Helv Physiol Pharmacol Acta. 1956;14(4):383-90
13405359
J Pharmacol Exp Ther. 1958 Mar;122(3):295-300
13539755